Document:AXA/2025/FY/Earnings presentation: Difference between revisions
Content deleted Content added
doc_archive: publish snjra2xp9r (original transcript) (.md link) |
doc_archive: publish snjra2xp9r (original transcript) (.md link) |
||
| (5 intermediate revisions by the same user not shown) | |||
Line 20:
---
title: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf
source_file:
source_url: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf
doc_type: slides
pages: 49
tables:
converter: anchor_injection/1
tier: slides
parsed_at: '2026-07-
scanned_pages: []
residue:
- Table of contents
---
ORIGINAL_FRONTMATTER -->
Line 39 ⟶ 36:
{{pdf page|1|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== Full Year 2025 Earnings Presentation ===
* February 26, 2026
{{pdf page|2|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS AND THE USE OF NON-GAAP FINANCIAL MEASURES ===
'''Forward-looking statements'''
* Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans, expectations or objectives, and other information that is not historical information.
* Forward-looking statements are generally identified by words and expressions such as “expects”, “anticipates”, “may”, “plan,” “target” or any variations or similar terminology of these words and expressions, or conditional verbs such as, without limitations, “would” and “could”.
* In particular, the statements in this presentation regarding expected underlying earnings per share (“UEPS”) growth for 2026 are forward-looking statements to provide one-off guidance in the context of the last year of the Group’s current strategic plan.
* These statements in this presentation are based on Management’s current views and intentions and are subject to change.
* Undue reliance should not be placed on forward-looking statements because, by their nature, they are subject to known and unknown risks and uncertainties, many of which are outside AXA’s control, and can be affected by other factors that could cause AXA’s actual results to differ materially from those expressed in, or implied or projected by, such forward-looking statements.
* Each forward-looking statement speaks only at the date of this presentation.
* Please refer to Part 5 - “Risk Factors and Risk Management” of AXA’s Universal Registration Document for the year ended December 31, 2024 (the “2024 Universal Registration Document”) for a description of certain important factors, risks and uncertainties that may affect AXA’s business and/or results of operations.
* AXA specifically disclaims and undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as required by applicable laws and regulations.
'''Non-GAAP financial measures'''
* In addition, this presentation refers to certain non-GAAP financial measures, or alternative performance measures (“APMs”), used by Management in analyzing AXA’s operating trends, financial performance and financial position and providing investors with additional information that Management believes to be useful and relevant regarding AXA’s results.
* These non-GAAP financial measures generally have no standardized meaning and therefore may not be comparable to similarly labelled measures used by other companies.
* As a result, none of these non-GAAP financial measures should be considered in isolation from, or as a substitute for, the Group’s consolidated financial statements and related notes prepared in accordance with IFRS.
* “Underlying earnings”, UEPS (“underlying earnings per share”), “underlying return on equity”, “combined ratio” and “debt gearing” are APMs as defined in ESMA’s guidelines and the AMF’s related position statement issued in 2015.
* AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 (“AXA’s 2025 Activity Report”), on the pages indicated under the heading “USE OF NON-GAAP AND ALTERNATIVE PERFORMANCE MEASURES”.
* For further information on the above-mentioned and other non-GAAP financial measures used in this presentation, see the Glossary in AXA’s 2025 Activity Report.
'''Additional information'''
* AXA’s Activity Report as of December 31, 2025 is available on the AXA Group website (www.axa.com).
* AXA’s consolidated financial statements for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of an audit procedure by AXA’s statutory auditors.
Line 50 ⟶ 66:
{{pdf page|3|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== Contents ===
* 1. FY25 Highlights
* Thomas Buberl, Group CEO
* p.04
* 2. FY25 Business Performance
* Guillaume Borie, Global Head of Finance, Strategy, Underwriting, Risk, and Technology
* p.09
* 3. FY25 Financial Performance
* Alban de Mailly Nesle, Group CFO
* p.13
{{pdf page|4|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
== FY25 Highlights ==
{{pdf page|5|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== Full Year 2025 – Excellent performance ===
'''Full Year 2025 Key Performance Indicators'''
* +6% Revenues vs. FY24
* +8% Underlying EPS vs. FY24
* 16% ROE FY25
* 224% Solvency II ratio FY25
'''Delivering value for shareholders'''
* +8% DPS{{fn ref|1|2=Based on the dividend proposed by AXA’s Board of Directors on February 25, 2026 and subject to approval by the Shareholders’ Annual General Meeting to be held on April 30, 2026.}} growth and €1.25bn annual share buy back{{fn ref|2|2=Following AXA’s Board of Directors’ approval on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.}}
'''Outlook'''
* Confident to deliver underlying EPS growth at the upper end of 6%-8% target range for 2026
Line 82 ⟶ 106:
<div style="overflow-x:auto">
{| id="t1" class="wikitable fintable"
|+ Underlying earnings
|-
! style="text-align:left" |
! class="col-s" style="text-align:right" | Underlying earnings
|-
| style="text-align:left" | FY24
| style="text-align:right" | 8.1
|-
| style="text-align:left" | FY25
| style="text-align:right" | 8.4
|-
| style="text-align:left" | Change
| style="text-align:right" | +6%
|-
| style="text-align:left" |
| style="text-align:right" | +9%
|}
</div>
'''High organic growth'''
* +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%)
'''Record profitability'''
* Further margin expansion in P&C and L&H; improvement in efficiency
'''Scaling the business'''
* Continued investments in growth and technology
'''Consistent earnings growth while enhancing reserve prudence'''
<div class="ed-fn-notes" style="display:none">
</div>
Line 114 ⟶ 143:
=== Diversified franchise, well positioned in an attractive industry ===
* Protection gaps and emerging corporate risks
* Demographics driving demand for private retirement and healthcare
Line 143 ⟶ 171:
</div>
* Leading brand & high customer NPS
* Strong and diversified distribution
Line 161 ⟶ 188:
* Enhancing capital allocation discipline
* Building resilience
'''Confidence in sustaining earnings growth'''
{{pdf page|9|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
Line 171 ⟶ 199:
{{pdf page|10|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== Strong delivery across our businesses ===
<div style="overflow-x:auto">
{| id="t3" class="wikitable"
|+ Change for Gross written premiums at constant scope and FX and for underlying earnings at constant FX.
|-
! style="text-align:left" |
Line 182 ⟶ 208:
! style="text-align:right" | Underlying earnings
|-
| style="text-align:left" | <b>France
| style="text-align:right" | +6%
| style="text-align:right" | +7%
|-
| style="text-align:left" | <b>Europe
| style="text-align:right" | +6%
| style="text-align:right" | +9%
|-
| style="text-align:left" | <b>AXA XL
| style="text-align:right" | +4%
| style="text-align:right" | +9%
|-
| style="text-align:left" | <b>Asia, Africa & EME-LATAM
| style="text-align:right" | +13%
| style="text-align:right" | +6%
|}
</div>
Line 211 ⟶ 237:
* Underlying earnings +9%{{fn ref|2|2=Change FY25 vs. FY24 at constant FX.}} to €5.9bn
'''Retail and SME & Mid-market'''
* 2025: Growing volumes while expanding margins
* Beyond 2025: Investing to improve customer retention & expanding distribution footprint
'''AXA XL (Large & Specialty)'''
* 2025: Profitable growth with stable margins
* Beyond 2025: Capitalizing on attractive growth opportunities and continued cycle management
'''Key drivers'''
* Continued progress on efficiency
* Higher investment income
Line 235 ⟶ 259:
* €57bn GWP
* Short-term
* Underlying earnings +7%{{fn ref|1|2=Change FY25 vs. FY24 at constant FX.}} to €3.5bn
<div style="overflow-x:auto">
{| id="t4" class="wikitable"
|+ Strategic Priorities
|-
! style="text-align:left" |
Line 264 ⟶ 286:
<div class="ed-fn-notes" style="display:none">
{{fn note|1=1|2=
</div>
Line 275 ⟶ 297:
{{pdf page|14|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== P&C – Continued disciplined growth ===
<div style="overflow-x:auto">
{| id="t5" class="wikitable fintable"
|+ GWP & Other Revenues (
|-
! style="text-align:left" | In Euro billion
! class="col-
! class="col-
! class="col-s" style="text-align:right" | Change
! class="col-s" style="text-align:right" | o/w pricing{{fn ref|1|2=Price effect.}}
Line 292 ⟶ 310:
|-
| style="text-align:left" | Commercial lines
| style="text-align:right" | —
| style="text-align:right" | 35.8
| style="text-align:right" | +4%
Line 299 ⟶ 317:
|-
| style="text-align:left" | AXA XL Reinsurance
| style="text-align:right" | —
| style="text-align:right" | 2.6
| style="text-align:right" | +8%
Line 306 ⟶ 324:
|-
| style="text-align:left" | Retail lines
| style="text-align:right" | —
| style="text-align:right" | 19.7
| style="text-align:right" | +7%
Line 312 ⟶ 330:
| style="text-align:right" | +2%
|-
| style="text-align:left" | <b>Total</b>
| style="text-align:right" | <b>56.5</b>
| style="text-align:right" | <b>58.0</b>
| style="text-align:right" | <b>+5%</b>
| style="text-align:right" | —
| style="text-align:right" | —
|}
</div>
'''Commercial lines'''
* Continued pricing momentum and volume growth in Mid-market and SME
* Growing in lines of business with attractive margins while remaining focused on retention at AXA XL Insurance
'''AXA XL Reinsurance'''
* Growth supported by alternative capital
'''Retail lines'''
* Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25)
Line 333 ⟶ 356:
{{pdf page|15|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== P&C – Delivering further margin expansion while enhancing reserve prudence ===
<div style="overflow-x:auto">
Line 341 ⟶ 362:
|-
! style="text-align:left" |
! class="col-
! class="col-
|-
| style="text-align:left" | Undiscounted CY loss ratio (ex Nat Cat)
Line 364 ⟶ 385:
| style="text-align:right" | -3.5%
|-
| style="text-align:left" |
| style="text-align:right" | <b>91.0%</b>
| style="text-align:right" | <b>90.6%</b>
|}
</div>
Line 377 ⟶ 398:
* Lower reliance on prior year reserve development
* Taking advantage of a good year to enhance reserve prudence
{{pdf page|16|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== P&C – Earnings growth from higher underwriting and financial result ===
'''Underlying Earnings'''
* Better underwriting result from strong volume growth and improved all-year combined ratio while enhancing reserve prudence
* Increase in investment income reflecting higher volumes and better reinvestment yields on fixed income assets
* Higher unwind of discount of claims reserves, in line with guidance
* Unfavorable forex impact notably due to USD depreciation vs. EUR
<div style="overflow-x:auto">
{| id="t7" class="wikitable fintable"
|+ Underlying Earnings
|-
! style="text-align:left" |
! class="col-
|-
| style="text-align:left" | FY24
| style="text-align:right" | 5,510
|-
| style="text-align:left" | Volume growth
| style="text-align:right" | +292
|-
| style="text-align:left" | Margin improvement
| style="text-align:right" | +189
|-
| style="text-align:left" | Investment income
| style="text-align:right" | +435
|-
| style="text-align:left" | Insurance finance expenses
| style="text-align:right" | -235
|-
Line 413 ⟶ 436:
| style="text-align:right" | -150
|-
| style="text-align:left" | <b>FY25</b>
| style="text-align:right" | <b>5,872</b>
|-
| style="text-align:left" |
| style="text-align:right" | +9%
|}
</div>
'''Underwriting result{{fn ref|1|2=Underwriting result includes expenses.}}'''
* Volume growth
* Margin improvement
'''Financial result'''
* Investment income
* Insurance finance expenses
Change at constant FX.
<div class="ed-fn-notes" style="display:none">
{{fn note|1=1|2=Underwriting result includes expenses.}}
</div>
{{pdf page|17|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== Life & Health – Strong growth in premiums, positive net flows ===
<div style="overflow-x:auto">
{| id="t8" class="wikitable fintable"
|+ Life GWP & Other Revenues
|-
! style="text-align:left" | In Euro billion
! class="col-
! class="col-
! class="col-s" style="text-align:right" | Change
|-
| style="text-align:left" | Protection
| style="text-align:right" | —
| style="text-align:right" | 17.3
| style="text-align:right" | +11%
|-
| style="text-align:left" | Unit-linked
| style="text-align:right" | —
| style="text-align:right" | 9.3
| style="text-align:right" | +13%
|-
| style="text-align:left" | Capital light G/A
| style="text-align:right" | —
| style="text-align:right" | 9.0
| style="text-align:right" | +7%
|-
| style="text-align:left" | Traditional G/A
| style="text-align:right" | —
| style="text-align:right" | 1.9
| style="text-align:right" | -7%
|-
| style="text-align:left" | <b>Total</b>
| style="text-align:right" | <b>34.5</b>
| style="text-align:right" | <b>37.5</b>
| style="text-align:right" | <b>+9%</b>
|}
</div>
<div style="overflow-x:auto">
{| id="t9" class="wikitable
|+ Health GWP & Other Revenues
|-
! style="text-align:left" | In Euro billion
!
!
!
|-
| style="text-align:left" | Individual
| style="text-align:right" | —
| style="text-align:right" | 10.5
| style="text-align:right" | +6%
|-
| style="text-align:left" | Group
| style="text-align:right" | —
| style="text-align:right" | 8.5
| style="text-align:right" | +4%
|-
| style="text-align:left" | <b>Total</b>
| style="text-align:right" | <b>17.5</b>
| style="text-align:right" | <b>19.0</b>
| style="text-align:right" | <b>+5%</b>
|}
</div>
* o/w FY25 Employee Benefits{{fn ref|1|2=Including both short-term and long-term Employee Benefits GWP and other revenues.}}
* Euro 12.9 billion (+4% vs. FY24)
<div style="overflow-x:auto">
{| id="t10" class="wikitable fintable"
|+ Net flows: €+5.4bn vs. €+1.5bn in FY24
|-
! style="text-align:left" | In Euro billion
! class="col-s" style="text-align:right" | FY25
|-
| style="text-align:left" | Protection
Line 521 ⟶ 550:
|}
</div>
<div class="ed-fn-notes" style="display:none">
Line 531 ⟶ 558:
=== Life & Health – Strong volume growth in Savings and Protection impacted by higher interest rates on discounting ===
* PVEP was impacted by higher interest rates on discounting despite strong growth in Life volumes
* NB CSM was driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits
Line 538 ⟶ 566:
<div style="overflow-x:auto">
{| id="t11" class="wikitable fintable"
|+ PVEP
|-
! style="text-align:left" | In Euro billion
! class="col-
! class="col-
! class="col-s" style="text-align:right" | Change
|-
| style="text-align:left" | Protection & Health
| style="text-align:right" | —
| style="text-align:right" | 31.4
| style="text-align:right" | -4%
|-
| style="text-align:left" | Unit-Linked
| style="text-align:right" | —
| style="text-align:right" | 8.5
| style="text-align:right" | +18%
|-
| style="text-align:left" | Capital-light G/A
| style="text-align:right" | —
| style="text-align:right" | 7.8
| style="text-align:right" | -10%
|-
| style="text-align:left" | Traditional G/A
| style="text-align:right" | —
| style="text-align:right" | 1.7
| style="text-align:right" | -10%
|-
| style="text-align:left" | <b>Total
| style="text-align:right" | <b>50.9</b>
| style="text-align:right" | <b>49.4</b>
| style="text-align:right" | <b>-2%</b>
|}
</div>
Line 574 ⟶ 602:
<div style="overflow-x:auto">
{| id="t12" class="wikitable fintable"
|+ NB CSM (pre-tax
|-
! style="text-align:left" | In Euro billion
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:
|-
| style="text-align:left" | NB CSM (pre-tax)
| style="text-align:right" | 2.2
| style="text-align:right" | 2.2
| style="text-align:
|}
</div>
Line 590 ⟶ 618:
<div style="overflow-x:auto">
{| id="t13" class="wikitable fintable"
|+ NBV (post-tax
|-
! style="text-align:left" | In Euro billion
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:
|-
| style="text-align:left" | NBV (post-tax)
| style="text-align:right" | 2.3
| style="text-align:right" | 2.2
| style="text-align:
|-
| style="text-align:left" | NBV margin
| style="text-align:right" | 4.4%
| style="text-align:right" | 4.5%
| style="text-align:
|}
</div>
{{pdf page|19|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== Life & Health – Growth in new business driving Normalized CSM growth ===
<!-- furniture -->
<div style="overflow-x:auto">
{| id="t14" class="wikitable fintable"
|+ Contractual Service Margin rollforward
|-
! style="text-align:left" |
! class="col-
|-
| style="text-align:left" | FY24
Line 651 ⟶ 672:
| style="text-align:right" | -1.4
|-
| style="text-align:left" | <b>FY25</b>
| style="text-align:right" | <b>33.0</b>
|}
</div>
'''Normalized CSM growth +2%'''
* Normalized CSM up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates
* Economic variance reflecting government spreads tightening and positive equity market returns
* Operating variance driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland
* FX impact mainly from JPY and HKD depreciation
'''CSM breakdown'''
* FY24 o/w Life: 25.8
* FY24 o/w Health: 7.7
* FY25 o/w Life: 25.4
* FY25 o/w Health: 7.6
<div class="ed-fn-notes" style="display:none">
{{fn note|1=1|2=Change at constant scope and FX.}}
</div>
<!-- furniture -->
{{pdf page|20|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
Line 680 ⟶ 699:
<div style="overflow-x:auto">
{| id="
|+ Underlying Earnings
|-
! style="text-align:left" |
! class="col-s" style="text-align:right" | FY24
!
! style="text-align:left" | Long-term result incl. CSM release
! class="col-s" style="text-align:right" | Financial result
! class="col-s" style="text-align:right" | Tax, FX and others
! class="col-s" style="text-align:right" | FY25
|-
| style="text-align:left" | —
| style="text-align:right" | 3,323
| style="text-align:left" | +60
| style="text-align:left" | +156
| style="text-align:right" | -11
| style="text-align:right" | -27
| style="text-align:right" | 3,501
|-
| style="text-align:left" | Short-term technical margin
| style="text-align:right" | 415
| style="text-align:
| style="text-align:left" | —
| style="text-align:right" | —
| style="text-align:right" | —
| style="text-align:right" | 479
|-
| style="text-align:left" | Long-term result incl. CSM release
| style="text-align:right" | 2,680
| style="text-align:
| style="text-align:left" | —
| style="text-align:right" | —
| style="text-align:right" | —
| style="text-align:right" | 2,804
|-
| style="text-align:left" | Financial result
| style="text-align:right" | 975
| style="text-align:
| style="text-align:left" | —
| style="text-align:right" | —
| style="text-align:right" | —
| style="text-align:right" | 946
|-
| style="text-align:left" | Tax &
| style="text-align:right" | -748
| style="text-align:
| style="text-align:left" | —
| style="text-align:right" | —
| style="text-align:right" | —
| style="text-align:right" | -728
|}
</div>
*in billions*
* o/w Life: 2.6 → 2.7, +4% vs. FY24
* o/w Health: 0.7 → 0.8, +17% vs. FY24
Change at constant FX.
* Strong short-term technical margin reflecting underwriting and claims initiatives that more than offset the impact of legislative change on the recoverability of value added tax in Mexico (€-0.1bn)
* Higher long-term results from increase in CSM release (+8%) reflecting growth in reserve base, including from favorable equity market performance, and better margins
{{pdf page|21|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
Line 747 ⟶ 766:
<div style="overflow-x:auto">
{| id="
|+ In Euro billion
|-
Line 753 ⟶ 772:
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
! class="col-
|-
| style="text-align:left" | Property & Casualty
Line 775 ⟶ 794:
| style="text-align:right" | -
|-
|-
| style="text-align:left" | Non-financial flows
| style="text-align:right" | -0.5
| style="text-align:right" | +2.1
| style="text-align:right" | —
|-
| style="text-align:left" | <i>o/w capital gains from AXA IM disposal</i>
| style="text-align:right" |
| style="text-align:right" | +2.2
| style="text-align:right" | —
|-
| style="text-align:left" | Financial flows (incl. RCG)
| style="text-align:right" | +0.3
| style="text-align:right" | -0.7
| style="text-align:right" | —
|-
|}
</div>
* Strong performance from insurance businesses
* Stable holding cost, expected to remain at current level in 2026
'''Net Income'''
* Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM
* Lower financial flows reflecting unfavorable forex impact
<div style="overflow-x:auto">
{| id="
|+ Underlying earnings per share
|-
! style="text-align:left" | In Euro
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
|-
| style="text-align:left" | Underlying earnings per share
| style="text-align:right" | 3.59
| style="text-align:right" | 3.86
|-
| style="text-align:left" | Change
| style="text-align:right" | —
| style="text-align:right" | +8%
|}
Line 821 ⟶ 848:
* +6% from earnings growth
* including -1% from temporary earnings dilution from AXA IM sale due to the timing of anti-dilutive share buyback
* +3% from capital management
* -2% from forex
<div class="ed-fn-notes" style="display:none">
{{fn note|1=1|2=Change at constant FX for underlying earnings and net income. Change on reported basis for underlying earnings per share.}}
</div>
{{pdf page|22|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== Shareholders’ Equity ===
<div style="overflow-x:auto">
{| id="
|+ Shareholders’ equity{{fn ref|1|2=Shareholders’ equity Group share.}}
|-
! style="text-align:left" | In Euro billion
! class="col-
! class="col-
! class="col-
|-
| style="text-align:left" | SHE (excl. OCI)
Line 862 ⟶ 879:
| style="text-align:right" | -7.2
| style="text-align:right" | -6.8
|-
| style="text-align:left" | <b>Shareholders' equity</b>
| style="text-align:right" | <b>49.9</b>
| style="text-align:right" | <b>45.5</b>
| style="text-align:right" | <b>47.2</b>
|-
| style="text-align:left" | SHE (excl. OCI & undated subordinated debt)
Line 881 ⟶ 903:
<div style="overflow-x:auto">
{| id="
|+ FY24 to FY25 and HY25 to FY25 Shareholders' equity bridge
|-
! style="text-align:left" | In Euro billion
! class="col-
! class="col-
|-
| style="text-align:left" | <b>Opening Shareholders' equity</b>
| style="text-align:right" | <b>49.9</b>
| style="text-align:right" | <b>45.5</b>
|-
| style="text-align:left" | Change in Net OCI
Line 901 ⟶ 924:
| style="text-align:left" | Dividend
| style="text-align:right" | -4.6
| style="text-align:right" |
|-
| style="text-align:left" | Annual share buyback
| style="text-align:right" | -1.2
| style="text-align:right" |
|-
| style="text-align:left" | Anti-dilutive share buyback following the sale of AXA IM
Line 923 ⟶ 946:
| style="text-align:right" | 0.3
|-
| style="text-align:left" | <b>Closing Shareholders' equity</b>
| style="text-align:right" | <b>47.2</b>
| style="text-align:right" | <b>47.2</b>
|}
</div>
Line 935 ⟶ 958:
{{pdf page|23|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== Higher organic cash remittance and robust cash position at Holding ===
<div style="overflow-x:auto">
{| id="
|+ Net Cash Remittance (
|-
! style="text-align:left" | In Euro billion
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | FY25
|-
| style="text-align:left" | Proceeds related to in-force treaties{{fn ref|2|2=2. €0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.}}
| style="text-align:right" | 0.6
| style="text-align:right" | —
|-
| style="text-align:left" | Ordinary cash remittance
Line 956 ⟶ 975:
| style="text-align:right" | 7.5
|-
| style="text-align:left" | <b>Total Net Cash Remittance</b>
| style="text-align:right" | <b>7.7</b>
| style="text-align:right" | <b>7.5</b>
|-
| style="text-align:left" | Remittance ratio{{fn ref|1|2=1. Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.}}
| style="text-align:right" | 82%
| style="text-align:right" | 82%
Line 967 ⟶ 986:
<div style="overflow-x:auto">
{| id="
|+
|-
| style="text-align:left" | <b>FY24 Cash position</b>
| style="text-align:right" | <b>4.0</b>
|-
| style="text-align:left" | Net cash remittance from subsidiaries
Line 994 ⟶ 1,013:
| style="text-align:right" | +3.1
|-
|}
</div>
<div class="ed-fn-notes" style="display:none">
{{fn note|1=1|2=1. Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.}}
{{fn note|1=2|2=2. €0.6bn proceeds related to L&
</div>
{{pdf page|24|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== Solvency II at 224% ===
<div style="overflow-x:auto">
{| id="
|+ Eligible Own Funds (EOF), Solvency Capital Requirement (SCR), and Solvency II ratio
|-
! style="text-align:left" | In Euro billion
! class="col-s" style="text-align:right" | FY24
! class="col-s" style="text-align:right" | Regulatory & model changes
Line 1,021 ⟶ 1,038:
! class="col-s" style="text-align:right" | Dividend & annual share buyback
! class="col-s" style="text-align:right" | Management actions, debt & other
! class="col-
|-
| style="text-align:left" | Eligible Own Funds (EOF)
Line 1,031 ⟶ 1,048:
| style="text-align:right" | -6.0
| style="text-align:right" | -0.1
| style="text-align:right" | <b>56.4</b>
|-
| style="text-align:left" | Solvency II ratio
Line 1,041 ⟶ 1,058:
| style="text-align:right" | -24pts
| style="text-align:right" | +2pts
| style="text-align:right" | <b>224%</b>
|-
| style="text-align:left" | Solvency Capital Requirement (SCR)
Line 1,051 ⟶ 1,068:
| style="text-align:right" | 0.0
| style="text-align:right" | -0.2
| style="text-align:right" | <b>25.2</b>
|}
</div>
* Dividend & annual share buyback details
* Foreseeable dividends: €-4.8bn
* Provision for annual share buyback for 2026: €-1.25bn
<div style="overflow-x:auto">
{| id="
|+ Key sensitivities
|-
| style="text-align:left" | Ratio as of December 31, 2025
| style="text-align:right" | <b>224%</b>
|-
| style="text-align:left" | Interest rate +50bps
Line 1,106 ⟶ 1,123:
=== Solvency II – impact of the end of grandfathering period and Solvency II revision ===
* Ratio as of 31/12/2025: 224%
* Impact of the end of grandfathering period on January 1, 2026: -10pts to 215%
* Euro 2.4 billion grandfathered debt no longer eligible as capital from January 1, 2026
* Impact of Solvency II revision to come into effect in 1Q27: +17pts{{fn ref|1|2=Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.}}
* No change expected in organic capital generation
* Additional capital flexibility
Line 1,135 ⟶ 1,137:
== Conclusion ==
{{pdf page|27|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
Line 1,146 ⟶ 1,148:
{{pdf page|28|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
== Q&A Full Year 2025 Earnings February 26, 2026 ==
{{pdf page|29|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== AXA Investor Relations – Keep in touch ===
* March: Roadshows — Europe and US
* May 5: 1Q25 Activity Indicators — Paris
Line 1,161:
* September 21: AXA Investor Day — London
* Investor Relations
* +33 1 40 75 48 42
* investor.relations@axa.com
* www.axa.com
{{pdf page|30|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
Line 1,184 ⟶ 1,177:
* 2. Additional P&C disclosures p.36
* 3. Additional IFRS17 disclosures p.41
* 4. Sustainability p.44
{{pdf page|32|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== Gross financial debt and maturity breakdown as of December 31st, 2025 ===
In Euro billion
<div style="overflow-x:auto">
{| id="
|+ Gross financial debt{{fn ref|1,2}}
|-
! style="text-align:left" | In Euro billion
! class="col-
! class="col-
! class="col-
|-
| style="text-align:left" | Debt gearing
| style="text-align:right" | 20.6%
| style="text-align:right" | 22.3%
| style="text-align:right" | —
|-
| style="text-align:left" | Tier 1
Line 1,215 ⟶ 1,213:
| style="text-align:right" | 5.8
|-
| style="text-align:left" | <b>Total</b>
| style="text-align:right" | <b>19.2</b>
| style="text-align:right" | <b>20.3</b>
| style="text-align:right" | <b>20.3</b>
|}
</div>
* Jan 1st 2026: o/w €0.4bn redeemed in Jan 2026
<div style="overflow-x:auto">
{| id="
|+ Contractual maturity breakdown
|-
! style="text-align:left" | In Euro billion
! class="col-s" style="text-align:right" | 2025
! class="col-s" style="text-align:right" | 2026
Line 1,241 ⟶ 1,238:
|-
| style="text-align:left" | Senior debt
| style="text-align:right" | —
| style="text-align:right" | —
| style="text-align:right" | —
| style="text-align:right" | 0.5
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" | —
| style="text-align:right" | 0.5
| style="text-align:right" |
|-
| style="text-align:left" | Tier 2
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" | 0.7
| style="text-align:right" |
| style="text-align:right" | 10.8
| style="text-align:right" |
|-
| style="text-align:left" | Tier 1
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
|-
|-
| style="text-align:left" | Tier 1
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" | 1.4
|-
| style="text-align:left" | Tier 2
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" | 0.7
| style="text-align:right" |
| style="text-align:right" | 0.2
| style="text-align:right" |
|}
</div>
<div style="overflow-x:auto">
{| id="
|+ Economic maturity breakdown{{fn ref|3|2=Economic maturity is taking into account the first date of step up calls on institutionally placed subordinated debt. For Solvency 2 RT1 debt, that has no step-up, the undated nature of the instrument is retained for the purpose of this diagram. This should not be construed, nor relied upon, as an indication that the instrument will not be called for redemption when callable. Such decision will depend on several factors, including our capital and liquidity position and the refinancing economics at the prevailing time.}}
|-
! style="text-align:left" | In Euro billion
! class="col-s" style="text-align:right" | 2025
! class="col-s" style="text-align:right" | 2026
Line 1,331 ⟶ 1,321:
|-
| style="text-align:left" | Senior debt
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" | 0.5
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" | 0.5
| style="text-align:right" |
|-
| style="text-align:left" | Tier 2
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" | 2.4
| style="text-align:right" |
| style="text-align:right" | 2.0
| style="text-align:right" | 0.7
| style="text-align:right" | 6.4
| style="text-align:right" |
| style="text-align:right" | 0.7
|-
| style="text-align:left" | Tier 1
| style="text-align:right" | —
| style="text-align:right" | 0.1
| style="text-align:right" |
| style="text-align:right" | 0.1
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" | 4.0
|-
|-
| style="text-align:left" | Tier 1
| style="text-align:right" |
| style="text-align:right" | 0.1
| style="text-align:right" |
| style="text-align:right" | 0.1
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" | 0.4
| style="text-align:right" |
| style="text-align:right" | 0.8
|-
| style="text-align:left" | Tier 2
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" |
| style="text-align:right" | 0.7
| style="text-align:right" | 0.2
| style="text-align:right" |
| style="text-align:right" |
|}
</div>
Line 1,413 ⟶ 1,397:
=== General Account Invested Assets ===
* Duration gap at -0.4 year
* Euro 450 billion
<div style="overflow-x:auto">
{| id="
|+
|-
! style="text-align:left" |
! class="col-s" style="text-align:right" | FY25
! class="col-
|-
| style="text-align:left" | Fixed income
Line 1,464 ⟶ 1,449:
| style="text-align:right" | 0%
|-
| style="text-align:left" | <b>Total Insurance Invested Assets {{fn ref|4|2=Please refer to the financial supplement for more details.}}</b>
| style="text-align:right" | <b>450</b>
| style="text-align:right" | <b>100%</b>
|}
</div>
Line 1,481 ⟶ 1,466:
<div style="overflow-x:auto">
{| id="
|+ Structured and Private Credit assets
|-
! style="text-align:left" | Invested assets (100%) In Euro billion
! class="col-s" style="text-align:right" | FY25
! class="col-s" style="text-align:right" | % of total G/A{{fn ref|1|2=G/A: General Account}} portfolio
!
|-
| style="text-align:left" | Residential Mortgages
| style="text-align:right" | 16
| style="text-align:right" | 4%
| style="text-align:left" | - €6bn Dutch mortgages, NHG guaranteed<br/>- €10bn self originated mortgages in Switzerland (56% LTV) and Germany (45% LTV)
|-
| style="text-align:left" | CLO & ABS
| style="text-align:right" | 25
| style="text-align:right" | 6%
| style="text-align:left" | - 91% senior CLOs with circa 40% subordination (100% rated AAA-A and 92% rated AAA-AA)
|-
| style="text-align:left" | Infrastructure debt
| style="text-align:right" | 8
| style="text-align:right" | 2%
| style="text-align:left" | - Skewed towards resilient industries (Telecom, Utilities, Transport)
|-
| style="text-align:left" | CRE debt
| style="text-align:right" | 8
| style="text-align:right" | 2%
| style="text-align:left" | - Strong sector diversification (mainly logistics, residential and retail), mostly in Europe, and circa 60% LTV
|-
| style="text-align:left" | Mid-Market lending
| style="text-align:right" | 10
| style="text-align:right" | 2%
| style="text-align:left" | - Strong diversification with €8m average ticket<br/>- Investments through SMAs with strict underwriting guidelines : senior secured, covenants, restrictions on asset sales and sector allocation
|-
| style="text-align:left" | Other
| style="text-align:right" | 2
| style="text-align:right" | 0%
| style="text-align:left" | —
|-
| style="text-align:left" | <b>Total Structured and Private Credit Assets</b>
| style="text-align:right" | <b>69</b>
| style="text-align:right" | <b>15%</b>
| style="text-align:left" | o/w 54% participating
|}
</div>
<div class="ed-fn-notes" style="display:none">
Line 1,546 ⟶ 1,517:
{{pdf page|35|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== Investment portfolio – Fixed Income reinvestment ===
<div style="overflow-x:auto">
{| id="
|+ FY25 Fixed Income Reinvestment
|-
! class="col-m" style="text-align:right" | Share (%)
|-
| style="text-align:left" |
| style="text-align:right" | 32%
|-
| style="text-align:left" |
| style="text-align:right" | 40%
|-
| style="text-align:left" |
| style="text-align:right" | 21%
|-
| style="text-align:left" | Below investment grade credit
| style="text-align:right" | 7%
|-
| style="text-align:left" | <b>Total</b>
| style="text-align:right" | <b>Euro 57 billion</b>
|}
</div>
<div style="overflow-x:auto">
{| id="
|+ FY25 Fixed Income Reinvestment Yield
|-
Line 1,583 ⟶ 1,560:
</div>
* Average duration of 9 years
* Includes Euro 19.7 billion of Private & Structured Credit invested at 4.7% (CLOs, ABS, Infra & CRE debt, Fund financing and Private HY)
Line 1,598 ⟶ 1,575:
* 2. Additional P&C disclosures p.36
* 3. Additional IFRS17 disclosures p.41
* 4. Sustainability p.44
{{pdf page|37|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== AXA XL Insurance – Large Commercial & Specialty business ===
<div style="overflow-x:auto">
{| id="
|+ $19bn FY25 GWP by line of business
|-
Line 1,626 ⟶ 1,604:
<div style="overflow-x:auto">
{| id="
|+ $19bn FY25 GWP by geography
|-
Line 1,643 ⟶ 1,621:
</div>
* Top 3 globally
* Multinational Programs{{fn ref|2|2=Source: McKinsey}}
Line 1,649 ⟶ 1,628:
* Fine Art & Specie{{fn ref|4|2=Source: Industry Research Biz (January 2026)}}
* Qualitative chart: Profitability vs Ex-price growth (%)
* Property: High profitability, high ex-price growth
* Specialty: Medium-high profitability, medium-high ex-price growth
* Casualty: Medium profitability, medium ex-price growth
* Professional lines: Low-medium profitability, low-medium ex-price growth
<div class="ed-fn-notes" style="display:none">
Line 1,666 ⟶ 1,645:
{{pdf page|38|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== P&C – Focus on Reserves ===
<div style="overflow-x:auto">
{| id="
|+ Claims reserves ratio (Net undiscounted claims reserves/Net earned premiums)
|-
!
!
! style="text-align:right" | FY19
! style="text-align:right" | FY20
! style="text-align:right" | FY21
! style="text-align:right" | FY22
! style="text-align:right" | FY22
! style="text-align:right" | FY23
! style="text-align:right" | FY24
! style="text-align:right" | FY25
|-
|-
| style="text-align:left" |
| style="text-align:right" | 179%
| style="text-align:right" | 185%
| style="text-align:right" | 193%
Line 1,698 ⟶ 1,677:
|}
</div>
<div style="overflow-x:auto">
{| id="
|+ Technical reserves ratio (Net undiscounted technical reserves{{fn ref|1|2=Includes net undiscounted claims reserves and unearned premium reserves.}}/Net earned premiums)
|-
!
!
! style="text-align:right" | FY19
! style="text-align:right" | FY20
! style="text-align:right" | FY21
! style="text-align:right" | FY22
! style="text-align:right" | FY22
! style="text-align:right" | FY23
! style="text-align:right" | FY24
! style="text-align:right" | FY25
|-
|-
| style="text-align:left" |
| style="text-align:right" | 213%
| style="text-align:right" | 227%
| style="text-align:right" | 233%
Line 1,738 ⟶ 1,717:
=== P&C – 2026 Simplified Group Nat Cat Reinsurance Program{{fn ref|1|2=Excludes local reinsurance covers;}} ===
'''Insurance segment (occurrence protection)'''
<div style="overflow-x:auto">
{| id="
|+ In Euro
|-
! style="text-align:left" | Peril
! class="col-s" style="text-align:right" |
! class="col-s" style="text-align:right" |
! class="col-s" style="text-align:right" | Europe Earthquake
! class="col-s" style="text-align:right" | NA Hurricane
! class="col-s" style="text-align:right" | NA Earthquake
! class="col-s" style="text-align:right" | Per other perils{{fn ref|3|2=Other perils include Turkey earthquake, Other Europe and NA perils, South America Earthquake as well as a series of other secondary perils. Capacity varies by peril type.}}
|-
| style="text-align:left" |
| style="text-align:right" | 4.0bn
| style="text-align:right" | 2.1bn
| style="text-align:right" | 2.1bn
| style="text-align:right" | 1.2bn
| style="text-align:right" | 1.2bn
| style="text-align:right" |
|-
| style="text-align:left" | Retention
| style="text-align:right" | 600m
| style="text-align:right" | 450m
| style="text-align:right" | 400m
| style="text-align:right" | 600m{{fn ref|2|2=Varying retention between MX and NA (400m MX, 600m NA);}}
| style="text-align:right" | 600m{{fn ref|2|2=Varying retention between MX and NA (400m MX, 600m NA);}}
| style="text-align:right" | 400m
|}
</div>
* Alternative Capital & Cat Bonds
'''Key Takeaway'''
* Stable retention levels maintained in 2026 as in 2025
Line 1,785 ⟶ 1,762:
{{pdf page|40|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== P&C – AXA Group earnings deviation with different levels of Nat Cat cost{{fn ref|1|2=
<div style="overflow-x:auto">
{| id="
|+ Group underlying earnings deviation to average Nat Cat charges in 2026 (net of reinsurance, post-tax)
|-
! style="text-align:left" | Probability
! style="text-align:right" |
! style="text-align:right" | Deviation
|-
| style="text-align:left" | 1/20y
| style="text-align:right" | (95th)
| style="text-align:right" | €-1.2bn
|-
| style="text-align:left" | 1/10y
| style="text-align:right" | (90th)
| style="text-align:right" | €-0.8bn
|-
| style="text-align:left" | 1/5y
| style="text-align:right" | (80th)
| style="text-align:right" | €-0.4bn
|-
| style="text-align:left" | Median
| style="text-align:right" | (50th)
| style="text-align:right" | €+0.1bn
|-
| style="text-align:left" | 1/5y
| style="text-align:right" | (20th)
| style="text-align:right" | €+0.5bn
|-
| style="text-align:left" | 1/10y
| style="text-align:right" | (10th)
| style="text-align:right" | €+0.7bn
|-
| style="text-align:left" | 1/20y
| style="text-align:right" | (5th)
| style="text-align:right" | €+0.8bn
|}
</div>
* More severe years
* Negative deviation in ca. 40% of cases
* Less severe years
* Positive deviation in ca. 60% of cases
<div style="overflow-x:auto">
{| id="
|+ Average Expected Nat Cat charges (net of reinsurance, pre-tax)
|-
! style="text-align:left" | In Euro billion
!
!
|-
| style="text-align:left" | Average Expected Nat Cat charges
| style="text-align:right" | 2.6
| style="text-align:right" | 2.7
Line 1,846 ⟶ 1,828:
<div class="ed-fn-notes" style="display:none">
{{fn note|1=1|2=
</div>
Line 1,854 ⟶ 1,836:
* 2. Additional P&C disclosures p.36
* 3. Additional IFRS17 disclosures p.41
* 4. Sustainability p.44
{{pdf page|42|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== P&C – Margin Analysis ===
<div style="overflow-x:auto">
{| id="
|+ Technical Result In Euro million (pre-tax)
|-
! style="text-align:left" | In Euro million (pre-tax)
!
!
|-
| style="text-align:left" | <b>Current Accident Year Undiscounted Technical Margin</b>
| style="text-align:right" | <b>2,778</b>
| style="text-align:right" | <b>+707</b>
|-
| style="text-align:left" | Gross Earned Premiums
Line 1,883 ⟶ 1,865:
| style="text-align:right" | -0.4pt
|-
| style="text-align:left" |
| style="text-align:right" |
| style="text-align:right" |
|-
| style="text-align:left" | <b>Current Accident Year Discounting</b>
| style="text-align:right" | <b>2,009</b>
| style="text-align:right" | <b>+115</b>
|-
| style="text-align:left" | Discounting Ratio (in Combined Ratio points)
Line 1,893 ⟶ 1,879:
| style="text-align:left" | Current Accident Year Net Claims reserves
| style="text-align:right" | €19.0bn
| style="text-align:right" | —
|-
| style="text-align:left" | Duration
| style="text-align:right" | 4.0 years
| style="text-align:right" | —
|-
| style="text-align:left" | Current Accident Year Discount rate
| style="text-align:right" | 2.8%
| style="text-align:right" | —
|-
| style="text-align:left" | —
| style="text-align:right" | —
| style="text-align:right" | —
|-
| style="text-align:left" | <b>Prior Years' Reserve Development (PYD)</b>
| style="text-align:right" | <b>622</b>
| style="text-align:right" | <b>-341</b>
|-
| style="text-align:left" | PYD ratio
Line 1,913 ⟶ 1,903:
</div>
<div style="overflow-x:auto">
{| id="
|+ Financial Result In Euro million (pre-tax)
|-
! style="text-align:left" | In Euro million (pre-tax)
!
!
|-
| style="text-align:left" | <b>Investment Income</b>
| style="text-align:right" | <b>3,988</b>
| style="text-align:right" | <b>+435</b>
|-
| style="text-align:left" | FY25 Average Assets
| style="text-align:right" | €115bn
| style="text-align:right" | —
|-
| style="text-align:left" | Asset book yield
| style="text-align:right" | 3.5%
| style="text-align:right" | —
|-
| style="text-align:left" | FY25 Reinvestment yield{{fn ref|1|2=Reinvestment yield on fixed income assets.}}
| style="text-align:right" | 4.3%
| style="text-align:right" | —
|-
| style="text-align:left" |
| style="text-align:right" |
| style="text-align:right" |
|-
| style="text-align:left" | <b>Insurance Finance Expenses</b>
| style="text-align:right" | <b>-1,358</b>
| style="text-align:right" | <b>-235</b>
|-
| style="text-align:left" | FY24 Reserves at locked-in rate
| style="text-align:right" | €71bn
| style="text-align:right" | —
|-
| style="text-align:left" | Liability book yield
| style="text-align:right" | 1.9%
| style="text-align:right" | —
|}
</div>
'''FY25 sensitivity to Current Accident Year discount rate changes{{fn ref|2|2=Parallel shift of the full-year average yield curve (average of monthly opening discount rates of 2025) used for discounting FY25 current accident year net reserve.}}'''
* +25bps: €+0.2bn
* -25bps: €-0.2bn
<div style="overflow-x:auto">
{| id="
|+ Underlying Earnings
|-
! style="text-align:left" | In Euro million (pre-tax)
!
!
|-
| style="text-align:left" | <b>Underlying Earnings before tax</b>
| style="text-align:right" | <b>8,040</b>
| style="text-align:right" | <b>+681</b>
|-
| style="text-align:left" | Tax
Line 1,971 ⟶ 1,969:
| style="text-align:right" | -10
|-
| style="text-align:left" | <b>Underlying Earnings</b>
| style="text-align:right" | <b>5,872</b>
| style="text-align:right" | <b>+501</b>
|-
| style="text-align:left" | Growth vs. FY24 (at constant FX)
| style="text-align:right" | —
| style="text-align:right" | +9%
|}
</div>
'''2026e Insurance Finance Expenses (pre-tax)'''
*
* +25bps: ~ €-50m
* -25bps: ~ €+50m
<div class="ed-fn-notes" style="display:none">
{{fn note|1=1|2=Reinvestment yield on fixed income assets.}}
Line 1,998 ⟶ 1,995:
=== L&H – Margin Analysis ===
<div style="overflow-x:auto">
{| id="
|+ Technical Result (In Euro million, pre-tax)
|-
! style="text-align:left" | In Euro million, pre-tax
! class="col-
! class="col-
|-
| style="text-align:left" | <b>Short-term Technical Margin</b>
| style="text-align:right" | <b>479</b>
| style="text-align:right" | <b>+60</b>
|-
| style="text-align:left" | Gross Earned Premiums
Line 2,021 ⟶ 2,017:
| style="text-align:right" | -0.1pts
|-
| style="text-align:left" | <b>Long-term Technical Margin</b>
| style="text-align:right" | <b>2,804</b>
| style="text-align:right" | <b>+156</b>
|-
| style="text-align:left" | CSM release
Line 2,037 ⟶ 2,033:
* Incl. recapture of Laya
<div style="overflow-x:auto">
{| id="
|+ Financial Result (In Euro million, pre-tax)
|-
! style="text-align:left" | In Euro million, pre-tax
!
!
|-
| style="text-align:left" | <b>Investment Income (non-VFA only)</b>
| style="text-align:right" | <b>2,484</b>
| style="text-align:right" | <b>-1</b>
|-
| style="text-align:left" | FY25 Average Assets
| style="text-align:right" | €98bn
| style="text-align:right" | —
|-
| style="text-align:left" | Asset book yield
| style="text-align:right" | 2.5%
| style="text-align:right" | —
|-
| style="text-align:left" | FY25 Reinvestment yield{{fn ref|1|2=Reinvestment yield on fixed income assets.}}
| style="text-align:right" | 3.8%
| style="text-align:right" | —
|-
| style="text-align:left" | <b>Insurance Finance Expenses (non-VFA only)</b>
| style="text-align:right" | <b>-1,538</b>
| style="text-align:right" | <b>-9</b>
|-
| style="text-align:left" | FY24 Reserves at locked-in rate
| style="text-align:right" | €62bn
| style="text-align:right" | —
|-
| style="text-align:left" | Liability book yield
| style="text-align:right" | 2.5%
| style="text-align:right" | —
|}
</div>
<div style="overflow-x:auto">
{| id="
|+ Life & Health FY25 CSM Key Sensitivities
|-
! style="text-align:left" | (in Euro billion)
! class="col-
|-
| style="text-align:left" | <b>Baseline</b>
| style="text-align:right" | <b>33.3</b>
|-
| style="text-align:left" | Interest rates +50bps
Line 2,136 ⟶ 2,104:
| style="text-align:left" | Equities -25%
| style="text-align:right" | -2.2
|}
</div>
<div style="overflow-x:auto">
{| id="t44" class="wikitable"
|-
! style="text-align:left" | In Euro million, pre-tax
! style="text-align:right" | FY25
! style="text-align:right" | Change
|-
| style="text-align:left" | <b>Underlying Earnings before tax</b>
| style="text-align:right" | <b>4,229</b>
| style="text-align:right" | <b>+205</b>
|-
| style="text-align:left" | Tax
| style="text-align:right" | -800
| style="text-align:right" | 65
|-
| style="text-align:left" | Affiliates, Minority interests & Other
| style="text-align:right" | 72
| style="text-align:right" | -51
|-
| style="text-align:left" | <b>Underlying Earnings</b>
| style="text-align:right" | <b>3,501</b>
| style="text-align:right" | <b>+219</b>
|-
| style="text-align:left" | Growth vs. FY24 (at constant FX)
| style="text-align:right" | —
| style="text-align:right" | +7%
|}
</div>
Line 2,148 ⟶ 2,145:
* 2. Additional P&C disclosures p.36
* 3. Additional IFRS17 disclosures p.41
* 4. Sustainability p.44
{{pdf page|45|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
=== Expanding AXA’s role in society: AXA for Progress Index{{fn ref|1|2=AXA’s Sustainability Statement is subject to completion of a certification with limited assurance by AXA Group’s auditors and will be presented to the AXA Board of Directors for approval on March 11, 2026.}} ===
<div style="overflow-x:auto">
{| id="
|+ As a GLOBAL INVESTOR
|-
! style="text-align:left" |
! style="text-align:right" | Target
! style="text-align:right" | 2025 Result
|-
| style="text-align:left" | €5bn{{fn ref|2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}} in climate transition financing per year
| style="text-align:right" | €5bn{{fn ref|2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}}
| style="text-align:right" | €6.4bn
|-
| style="text-align:left" | >€500m{{fn ref|2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}} in community resilience financing per year
| style="text-align:right" | >€500m{{fn ref|2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}}
| style="text-align:right" | €1.4bn
|}
</div>
<div style="overflow-x:auto">
{| id="
|+ As a GLOBAL INSURER
|-
! style="text-align:left" |
! style="text-align:right" | Target
! style="text-align:right" | 2025 Result
|-
| style="text-align:left" | €6bn{{fn ref|3|2=Scope: AXA France, AXA Germany, AXA Switzerland, AXA UK & Ireland, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Unit: Gross Written Premiums (GWP); Timeframe: cumulative 2024-2026.}} in P&C GWP to support transition underwriting (cumulative 2024-2026)
| style="text-align:right" | €6bn{{fn ref|3|2=Scope: AXA France, AXA Germany, AXA Switzerland, AXA UK & Ireland, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Unit: Gross Written Premiums (GWP); Timeframe: cumulative 2024-2026.}}
| style="text-align:right" | €4.6bn
|-
| style="text-align:left" | >20,000{{fn ref|4|2=Scope: Commercial lines portfolio of AXA France, AXA Germany, AXA Switzerland, AXA UK, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Climate solutions & services include (i) training/education, (ii) risk assessment/awareness, (iii) gap analysis, (iv) prevention/adaptation solution, and/or (v) crisis management/remediation response. Timeframe: cumulative 2024-2026. Following strong support within the Group for climate adaption solutions & services in 2024 and 2025, AXA is proposing a significant increase in its target for the 2024-2026 period, from >9,000 to >20,000.}} climate adaptation solutions & services (cumulative 2024-2026) <i>Target revised in 2025</i>
| style="text-align:right" | >20,000{{fn ref|4|2=Scope: Commercial lines portfolio of AXA France, AXA Germany, AXA Switzerland, AXA UK, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Climate solutions & services include (i) training/education, (ii) risk assessment/awareness, (iii) gap analysis, (iv) prevention/adaptation solution, and/or (v) crisis management/remediation response. Timeframe: cumulative 2024-2026. Following strong support within the Group for climate adaption solutions & services in 2024 and 2025, AXA is proposing a significant increase in its target for the 2024-2026 period, from >9,000 to >20,000.}}
| style="text-align:right" | 19,698<br/>Cumulative 2024-2025
|-
| style="text-align:left" | >20m{{fn ref|5|2=Low-income to mass market segments in emerging markets and modest income segments in mature markets.}} inclusive insurance customers by 2026
| style="text-align:right" | >20m{{fn ref|5|2=Low-income to mass market segments in emerging markets and modest income segments in mature markets.}}
| style="text-align:right" | 20.6m
|}
</div>
<div style="overflow-x:auto">
{| id="
|+ As a COMPANY
|-
! style="text-align:left" |
! class="col-s" style="text-align:right" | Target
! class="col-m" style="text-align:right" | 2025 Result
|-
| style="text-align:left" | >80,000{{fn ref|6|2=Number of employees who have been trained on climate change adaptation, completing a training under the AXA Sustainability Academy. Timeframe: cumulative 2024-2026.}} AXA Group employees trained on climate adaptation by 2026
| style="text-align:right" | >80,000{{fn ref|6|2=Number of employees who have been trained on climate change adaptation, completing a training under the AXA Sustainability Academy. Timeframe: cumulative 2024-2026.}}
| style="text-align:right" | 46,420
|-
| style="text-align:left" | Contribute to Net-Zero -50%{{fn ref|7|2=Variation of AXA Group absolute carbon emissions (scope: energy Scopes 1 and 2, car fleet and business travel). Timeframe: 2019-2030.}} by 2030 in absolute carbon emissions and offset of residual emissions{{fn ref|8|2=Carbon credits from projects that focus on capturing and storing carbon emissions from the atmosphere using nature-based or technical solutions (e.g. restorative agriculture, forest restoration or carbon capture and storage).}}
| style="text-align:right" | -
| style="text-align:right" | -64%<br/>Reduction against 2019
|-
| style="text-align:left" | 50% Percentage of AXA Group employees engaged in volunteering activities by 2026
| style="text-align:right" | 50%
| style="text-align:right" | 56%
|}
Line 2,220 ⟶ 2,226:
=== Sustainability Performance & Ratings ===
* 2025 percentile: 97th {{fn ref|1|2=The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026.}} in Dow Jones Best-in-Class Europe & World indices
'''MSCI'''
* 2025 score: AAA
'''CDP'''
* 2025 score: B
'''MORNINGSTAR SUSTAINALYTICS'''
* 2025 ESG Risk Rating: 17.0 – Low risk
'''FTSE RUSSELL An LSEG Business'''
* 2025 score: 4.3/5 in FTSE4Good Index Series
Line 2,244 ⟶ 2,254:
* Transversal & Other: includes AXA Assistance, AXA Liabilities Managers, AXA and other Central Holdings.
* AXA Investment Managers (until July 1, 2025): includes AXA Investment Managers, Select (previously referred to as Architas) and Capza which are fully consolidated and Asian joint ventures which are consolidated under the equity method.
'''Unless otherwise specified herein, all comparative figures for going back to 2023 are under the IFRS17/9 accounting standards that became effective on January 1, 2023. Figures for financial periods prior to 2023 have not been restated under IFRS17/9 and are presented under IFRS4, the applicable accounting standard that preceded the implementation of IFRS17/9'''
{{pdf page|48|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}}
Line 2,267 ⟶ 2,278:
* Full Year 2025 Earnings
* February 26, 2026
| |||